



MEDIA RELEASE

Ascend Biopharmaceuticals featured in Scientific American Worldview

26th June 2014. Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has been featured in the 2014 issue of [Scientific American Worldview](#) as a case study in immunotherapy treatments.

Scientific American Worldview is annual publication covering global innovations in biotechnology. The 2014 version is the 6th edition produced by the prestigious Scientific American magazine, with Ascend one of only 10 companies featured.

The article highlights Ascend's work in developing its two immunotherapy treatments – ASN 002 for basal cell carcinoma (skin cancer) and ASN-004 for metastatic breast cancer – in the context of rising global interest in immunotherapies as a safer and more effective method of treating cancer.

Ascend is featured on page 73 of Scientific American Worldview. The full piece can be read [here](#).

-ENDS-

For more information, please contact:

Clement Leong
Ascend Biopharmaceuticals, CEO
T: + 61 3 8606 3488
clementleong@ascendbiopharma.com

Ben Oliver
Buchan Consulting
T: + 613 8866 1205 / 0402 242 982
E: boliver@buchanwe.com.au

About Ascend Biopharmaceuticals

Ascend is a clinical-stage company developing innovative cancer treatments. The company focuses on identifying disease settings where targeting the disease microenvironment or important cell types can bring about meaningful improvements in clinical outcomes.

Ascend has two clinical stage immunotherapy programs that have undergone previous clinical evaluation. The first product, ASN-002, will be assessed in basal cell carcinoma patients while the second product, ASN-004, is a pan-cancer therapeutic vaccine that will be studied in early stage breast cancer.

For more information, please visit www.ascendbiopharma.com or call +61 3 8606 3488